摘要
靶向治疗和免疫治疗的进展已显著改善晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)患者的临床结局,并重塑其治疗范式。然而,多数患者终将面临耐药问题,其后线治疗选择有限,疗效不尽如人意,成为当前临床实践的突出难点。近年来,抗体偶联药物(antibody-drug conjugates,ADCs)以其高效低毒的潜在优势,成为该领域关注的焦点。本文系统综述肺癌ADCs治疗领域的研究进展,并探讨当前面临的挑战。
Advances in targeted therapy and immunotherapy have significantly improved clinical outcomes for patients with advanced non-small cell lung cancer(NSCLC),reshaping treatment paradigms.However,most patients ultimately face drug resistance,with limited options for subsequent therapies and suboptimal treatment efficacy,presenting a prominent challenge in current clinical practice.Antibody-drug conjugates(ADCs),characterized by high efficacy and favorable safety profiles,have emerged as a promising therapeutic frontier in recent years.This systematic review provides a comprehensive overview of the latest advancements in ADCs-based therapies for lung cancer,alongside discussions of the prevailing challenges in this rapidly evolving domain.
作者
钟雨玲
王婧怡
邬麟
Yuling ZHONG;Jingyi WANG;Lin WU(The Second Department of Thoracic Oncology,Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,China;Graduate Collaborative Training Base of Hunan Cancer Hospital,University of South China,Hengyang 421001,China)
出处
《中国肺癌杂志》
北大核心
2025年第8期621-628,共8页
Chinese Journal of Lung Cancer
基金
湖南省科技创新计划(No.2023SK4024)
国家重点临床专科科研专项项目(No.Z2023098)
湖南省卫生健康高层次人才重大科研专项(No.R2023125)
湖南省肿瘤医院“科研攀登计划”(No.ZX2020005-5)资助。
关键词
肺肿瘤
抗体偶联药物
生物标志物
毒性反应
Lung neoplasms
Antibody-drug conjugates
Biomarker
Toxic reactions
作者简介
通信作者:邬麟,E-mail:wulin-calf@vip.163.com。
